Table S1. Clinical events at follow-up.
| Study | Reference | BRS type | Stents, N | Patients, N | Follow-up | MACE % (n/N) | TLF % (n/N) | CD % (n/N) | ARC ST Def/Prob % (n/N) | MI % (n/N) | TV-MI % (n/N) | TVR % (n/N) | ID-TVR % (n/N) | TLR % (n/N) | ID-TLR % (n/N) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PROGRESS AMS | Erbel et al. 2007 | AMS1 | 71 | 63 | Baseline | − | − | − | − | − | − | − | − | − | − |
| Waksman et al. 2009 | 63 | 4 months | 23.8 (15/63) | 23.8 (15/63) | 0 (0/63) | 0 (0/63) | 0 (0/63) | 0 (0/63) | 39.7 (25/63) | 23.8 (15/63) | 39.7 (25/63) | 23.8 (15/63) | |||
| 60 | 12 months | 26.7 (16/60) | 23.8 (16/60) | 0 (0/60) | 0 (0/60) | 0 (0/60) | 0 (0/60) | 45.0 (27/60) | 26.7 (16/60) | 45.0 (27/60) | 26.7 (16/60) | ||||
| BIOSOLVE-I | Haude et al. 2013 | DREAMS 1G | 47 | 46 | Baseline | − | − | − | − | − | − | − | − | − | − |
| Waksman et al. 2013 | 46 | 6 months | − | 4.3 (2/46) | 0 (0/46) | 0 (0/46) | 0 (0/46) | 0 (0/46) | 4.3 (2/46) | 4.3 (2/46) | 4.3 (2/46) | 4.3 (2/46) | |||
| Haude et al. 2016 | 43 | 12 months | − | 7 (3/43) | 0 (0/43) | 0 (0/43) | 2.3 (1/43)° | 2.3 (1/43)° | 4.7 (2/43) | 4.7 (2/43) | 4.7 (2/43) | 4.7 (2/43) | |||
| 44* | 36 months | − | 6.6 (3/44) | 0 (0/44) | 0 (0/44) | 2.2 (1/44) | 2.2 (1/44) | 4.5 (2/44) | 4.5 (2/44) | 4.5 (2/44) | 4.5 (2/44) | ||||
| BIOSOLVE-II | Haude et al. 2015 | DREAMS 2G | 125 | 123 | Baseline | − | − | − | − | − | − | − | − | − | − |
| Haude et al. 2016 | 120 | 6 months | − | 3.3 (4/120) | 0.8 (1/120) | 0 (0/120) | − | 0.8 (1/120) | − | − | − | 1.7 (2/120) | |||
| 118 | 12 months | − | 3.4 (4/118) | 0.8 (1/118) | 0 (0/118) | − | 0.8 (1/118) | − | − | − | 1.7 (2/118) |
Data are shown as % (n/N); n, number of patients experiencing the event; N, overall number of patients at follow-up. *, patient missed 12-month follow-up but returned for 24- and 36-month clinical follow-up. °, peri-procedural TV-MI during 12-month follow-up angiography. ARC-ST, Academic Research Consortium stent thrombosis; CD, cardiac death; ID-TLR, ischemia-driven target lesion revascularization; ID-TVR, ischemia-driven target vessel revascularization; MACE, major adverse cardiac events; MI, myocardial infarction; TLF, target lesion failure; TLR, target lesion revascularization; TV-MI, target vessel myocardial infarction; TVR, target vessel revascularization.